Viemed Healthcare, Inc. (VMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company demonstrates strong financial performance with a 28% revenue increase and improved free cash flow. Despite regulatory challenges, the guidance is optimistic, supported by strategic growth in sleep and maternal health sectors. The share repurchase program signals confidence in long-term value. Positive sentiment is further reinforced by analysts' acknowledgment of potential upside in guidance. However, near-term pressures from NCD criteria and seasonal revenue patterns temper enthusiasm, resulting in a positive, yet moderate, stock price outlook.
Key Financial Performance
First Quarter Revenue $75.4 million, up 28% year-over-year. The increase is attributed to strong execution, growth in sleep business, and diversification of revenue streams.
PAP Therapy Patients 35,938 patients, up 57% year-over-year. Growth driven by increased diagnosis and treatment of obstructive sleep apnea and expansion of resupply patients.
Resupply Patients Up 47% year-over-year. Growth attributed to the expanding PAP base and increased focus on metabolic health.
Ventilator Rentals Revenue $35.4 million, up approximately 10% year-over-year. Growth driven by new patient start-up momentum and improved compliance rates.
Other Home Medical Equipment Rentals Revenue $16.2 million, up 25% year-over-year. Growth driven by patient growth across PAP, oxygen, and airway clearance.
Equipment and Supply Sales Revenue $17.5 million, more than doubling from $7.5 million in the prior year. Growth driven by sleep resupply and maternal health offerings.
Gross Profit $42.8 million, margin of 56.8%, up from 56.3% in the prior year. Improvement attributed to operational progress and revenue growth.
Adjusted EBITDA $14.3 million, 19% of revenue, up from $12.8 million (21.6% of revenue) in the prior year. Excluding prior year nonrecurring gains, margin expanded by 200 basis points year-over-year.
SG&A as Percentage of Revenue 46.1%, down from 48.1% in the prior year. Improvement reflects operating leverage and scaling of the business.
Net Income $2.6 million, flat year-over-year. Prior year included nonrecurring gains, and normalized earnings trajectory shows improvement.
Free Cash Flow $2.6 million, up from negative $5.7 million in the prior year. Improvement driven by increased operating cash flow and reduced capital expenditure.
Cash Flow from Operations $8.1 million, up from $2.9 million in the prior year. Reflects earnings growth across the platform.
Net CapEx $5.5 million, down from $8.5 million in the prior year. Reduction due to shift towards less capital-intensive revenue streams.
Trailing 12-Month Free Cash Flow $36.3 million, up from $11.6 million at the end of 2024. Reflects improved free cash flow profile of the business.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Sleep Business: PAP therapy patients grew 57% year-over-year, reaching nearly 36,000 patients. This growth is translating into a larger and steadily expanding base of resupply patients, providing greater visibility into future revenue.
Maternal Health: Serviced just under 4,000 new maternal health patients in markets where Lehan previously had no presence. The integration of Lehan has been smooth and accretive since day one.
Maternal Health Expansion: Expanded maternal health services into new markets using existing Viemed infrastructure, demonstrating scalability and potential for further growth.
Ventilation: New patient start-up momentum is building faster than expected, with 759 ventilator setups in March compared to 692 a year ago. Compliance among active ventilator patients has improved by nearly 20% since the NCD went into effect.
Free Cash Flow: Improved free cash flow by $8.3 million year-over-year, driven by stronger operating cash generation and reduced capital expenditure.
Revenue Diversification: Revenue from ventilator rentals decreased as a percentage of total revenue, while sleep resupply and maternal health services grew, reducing concentration risk and improving capital efficiency.
Regulatory Environment: CMS moratorium on new Medicare enrollments favors established providers like Viemed, creating a more rational competitive landscape. The absence of competitive bidding pressure on core products supports long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Ventilation Compliance Challenges: The turnover rate for patients under the new NCD criteria is higher than pre-NCD, creating near-term pressure on the net patient census. Patients experiencing noncompliance episodes risk losing access to their ventilators, which impacts patient care and could affect operational metrics.
Seasonal Revenue Patterns: Quarterly patient counts for resupply were down modestly due to seasonal deductible resets, which could impact short-term revenue consistency.
Regulatory Compliance Risks: The new NCD compliance framework creates challenges for patients with temporary compliance interruptions, potentially affecting their access to life-sustaining therapies. This could lead to operational and reputational risks.
Capital Efficiency Transition: The shift towards less capital-intensive categories like sleep resupply and maternal health reduces concentration risk but requires careful management to maintain profitability and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has updated its full-year 2026 revenue guidance to a range of $312 million to $320 million, narrowing and raising the low end of the previous range of $310 million to $320 million. Sequential revenue growth is expected to be in the range of 3% to 5% per quarter for the remainder of the year.
Adjusted EBITDA Guidance: The company reaffirmed its full-year 2026 adjusted EBITDA guidance in the range of $65 million to $69 million.
Capital Expenditures: The company updated its full-year 2026 net CapEx outlook to a range of 9% to 10.5% of net revenue, down from the prior expectation of 10% to 11.5%, reflecting improved capital efficiency.
Sleep Business Growth: The sleep business continues to scale, with PAP therapy patients growing 57% year-over-year. The company expects this growth to drive a more stable and predictable revenue stream over time.
Maternal Health Expansion: The maternal health segment is exceeding expectations, with plans to expand into additional Viemed markets throughout 2026.
Ventilation Business Trends: New patient start-up momentum in the ventilation business is building faster than expected, with March showing particularly strong ventilator setups. Compliance rates among active ventilator patients have improved by nearly 20% since the new NCD criteria went into effect.
Regulatory Environment: The company views the regulatory environment as favorable, with no material impact expected from competitive bidding or the CMS enrollment moratorium. These conditions are expected to support long-term sustainable growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During the first quarter, the company repurchased and canceled 150,000 shares of common stock under its 2026 share repurchase program at an average price of $9.29 per share, totaling $1.4 million. The program reflects confidence in the long-term value of the business and aims to be accretive to per-share value for continuing shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What factors could drive the company to the higher side of its guidance range?
A:All product lines have the potential to push towards the upside. Vent patients, new patient starts exceeding expectations, compliance metrics, maternal health business growth, and the outperforming sleep side are key contributors. If everything works well, there might be a possibility to increase guidance later.
Q:What are the limiting factors for growth in the maternal health business?
A:The limiting factors are primarily back office and fulfillment staffing rather than sales. The company is hiring and scaling up back office operations as fast as possible. Digital marketing also plays a significant role in driving growth.
Q:What operational efficiencies are being implemented, and what is the focus for the next 3 to 6 months?
A:The company is implementing AI, machine-based learning, and improvements in intake and logistics to enhance efficiencies. These measures aim to improve the cadence of setups and labor per order. Additionally, corporate G&A is not increasing proportionally with business line growth, leading to improved margins. The focus is on continuing to drive down G&A and enhance free cash flow.
Q:Review of Unclear Management Responses
A:Management provided clear and detailed answers to all questions, addressing the topics with sufficient clarity and specificity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMS
Lehan
Medicare
PAP
Sleep
Viemed market
access therapy
activity
capability
condition
criterion
denial
development
direction
dynamic
enrollment
focus
foundation
issue
market health
model
moratorium
number
offering
patient NCD
pattern
payer relationship
policy
process setup
profile
rate
result capital
risk uncertainty
security
sleep
standard
therapy compliance
trend
ventilation
ventilator
visibility
VMD Transcript
Viemed Healthcare, Inc. (VMD) Q1 2026 Earnings Call Transcript
Positive5-6
The company demonstrates strong financial performance with a 28% revenue increase and improved free cash flow. Despite regulatory challenges, the guidance is optimistic, supported by strategic growth in sleep and maternal health sectors. The share repurchase program signals confidence in long-term value. Positive sentiment is further reinforced by analysts' acknowledgment of potential upside in guidance. However, near-term pressures from NCD criteria and seasonal revenue patterns temper enthusiasm, resulting in a positive, yet moderate, stock price outlook.
Savaria Corporation (SIS:CA) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call summary indicates strong financial performance, with significant increases in revenue, net earnings, and EPS. The Q&A session reveals some uncertainties, but management's optimism about margin expansion and strategic acquisitions suggests positive sentiment. The combination of strong financial metrics, optimistic future guidance, and strategic growth plans supports a positive stock price outlook.
Viemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call Transcript
Positive3-5
The company reported strong financial results with record revenue growth, especially in the sleep and maternal health segments, and maintained stable margins. The strategic focus on expanding the Lehan acquisition and efficient capital allocation is promising. Despite some concerns about RTs and margin stability, the positive growth outlook and shareholder returns suggest a positive stock movement. The lack of market cap information limits precise impact prediction, but overall sentiment leans positive.
Viemed Healthcare, Inc. (VMD) Q3 2025 Earnings Call Transcript
Positive11-7
The company reported strong financial performance with 24% revenue growth and a 22.4% EBITDA margin. Positive factors include raised guidance, successful acquisitions, and increased share repurchases. Concerns about competitive bidding and unclear management responses in the Q&A may temper enthusiasm slightly, but overall sentiment remains positive due to growth and strategic initiatives.
VMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
